A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions about how to treat patients with early stage prostate cancer. The review, published in the Annals of Internal Medicine, shows that these tests can provide more detailed information about the cancer, but experts say more data is needed on the cost-effectiveness and clinical utility of these tests, as well as their impact on racial and ethnic groups, especially Black men. 

The Cardiovascular Research Foundation^® (CRF^®) is pleased to announce that registration for the second New York Valves: The Structural Heart Summit is now open. Following the outstanding success of last year’s inaugural conference, New York Valves 2025 is the world’s premier structural heart meeting and continues its mission to shape the future of structural heart care through collaboration, education, and innovation. The summit will take place June 25-27, 2025, at the Jacob K. Javits Convention Center, North in New York City.

In a paper recently published in the leading journal "The Lancet Digital Health", a scientific team led by Stanisa Raspopovic from MedUni Vienna looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many patients with neurological disorders and have been making headlines recently. As neural implants have an effect not only on a physical but also on a psychological level, researchers are calling for particular ethical and scientific care when conducting clinical trials.

A new study led by UCLA Health highlights the link between socioeconomic disadvantage, Medicaid insurance, and poorer survival rates after heart transplantation. Researchers found that Medicaid-insured heart transplant patients had a higher likelihood of developing cardiac allograft vasculopathy (CAV), a condition that affects transplanted hearts and can limit long-term survival. It has been reported that CAV contributes to more than 30% of all deaths in the first 5 to 10 years following heart transplantation.